View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 2, 2020

AbbVie partners with Jacobio Pharmaceuticals for cancer drugs

AbbVie has collaborated with Jacobio Pharmaceuticals for the development and commercialisation of SHP2 inhibitors that act on an important node in cancer and immune cells.

AbbVie has collaborated with Jacobio Pharmaceuticals for the development and commercialisation of SHP2 inhibitors that act on an important node in cancer and immune cells.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

SHP2 is a key protein mediator of cellular signalling via RAS / MAP kinase pathway. Several tumours have genetic mutations that lead to abnormal cancer cell growth, which depends on SHP2 activity.

The protein mediator is also involved in cytokine generation and immune cell response. SHP2 inhibition is believed to exhibit dual effects by decreasing cancer cell growth and regulating immune responses to produce anti-tumour activities.

Jacobio has designed its early clinical-stage SHP2 assets, JAB-3068 and JAB-3312, to selectively inhibit SHP2 activity.

Jacobio Pharmaceuticals CEO and chairman Yinxiang Wang said: “We look forward to a productive collaboration with AbbVie focused on rapidly advancing this novel SHP2 first-in-class therapy as a new approach for multiple cancer types.

“I am confident that this partnership will strengthen our R&D capabilities and ultimately bring benefits to cancer patients.”

As part of the deal, AbbVie will receive an exclusive license to the SHP2 portfolio. Jacobio will carry out early global clinical trials of JAB-3068 and JAB-3312 while AbbVie will fund R&D activities.

After completion, AbbVie will be responsible for development and commercialisation worldwide.

Jacobio holds an option to solely develop and commercialise the SHP2 programme in mainland China, Hong Kong and Macau. This option can be exercised before the launch of registrational trials.

AbbVie early development oncology vice-president and head Mohit Trikha said: “Jacobio’s SHP2 programme has the potential to treat cancer patients across many tumour types.

“By targeting a key node in both cancer and immune cell signalling pathways, SHP2 inhibition, both as a monotherapy and potentially in combination with other agents, may rapidly advance new treatment options for cancer patients.”

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology